AUTHORS
Jennifer R. Brown, MD, PhD, Katherine Chapis2, Hang Phan3, Robert Black4, Samantha Pazienza, BS5, Sandra Re, BSN, RN6, Svitlana Tyekucheva, PhD7, Lars van der Veen, PhD8, Michael Lahn, MD9, Philippe Armand, MD10, Eric Jacobsen, MD11, Inhye E Ahn, MD12, Matthew S Davids, MD, MMSc13
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 iOnctura, Geneva, Switzerland
9 iOnctura, Geneva, Switzerland
10 Mayo Clinic, Rochester, Minnesota, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
CLL is an incurable chronic disease with reduced benefit of BCL-2 inhibition following disease progression on BTK inhibitors (BTKi). Our group has shown promising clinical activity with the first-generation PI3Ki duvelisib and venetoclax, though clinical application has been limited by PI3Ki-related adverse events.
Roginolisib is a novel, oral, non-ATP competitive, conformation-selective small molecule inhibitor of PI3Kδ with a favorable safety profile. In the first-in-human study (NCT04328844), 44 patients (36 with solid tumors and 8 with follicular lymphoma) received roginolisib daily with no PI3Ki-related toxicities or dose modifications, including in 30% of patients treated >12 months. Roginolisib with venetoclax suppressed downstream PI3K/AKT pathways in preclinical models, and we have demonstrated ex vivo synergy between roginolisib and venetoclax in CLL patient samples resistant to BTKi.
This phase 1b/2 study (NCT06644183) is an investigator-sponsored, open-label randomized-controlled trial. In the initial 3+3 phase Ib safety lead-in reported here, patients received roginolisib (rogi) in two cohorts, first at 40 mg QD and then at 80 mg QD, in combination with venetoclax (ven) and rituximab (R) per standard of care. Ven ramp-up was initiated first over 5 weeks, with rogi added in cycle 2, and R given monthly in cycles 3-8, with ongoing rogi and ven. DLT evaluation occurred in cycle 2 when rogi was added to ven. In the phase 2, patients will be randomized 1:1 to receive either ven+R or rogi+ven+R.
Key inclusion criteria: CLL patients relapsed or refractory to two prior regimens (subsequently amended to one prior regimen), including exposure to a covalent BTKi. Key exclusion criteria: prior treatment with ven or PI3Ki in the last 6 months.
The primary objective is to compare the proportion of patients with undetectable measurable residual disease (uMRD) in bone marrow at 10-4 by the clonoSEQ® assay after 12 months of either rogi+ven+R or ven+R. Key secondary objectives include continuous evaluation of safety of rogi+ven+R.
Seven patients were enrolled in phase 1b, 3 in cohort 1 at 40 mg QD and 4 in cohort 2 at 80 mg QD. The patients included 6 males and 1 female, with median age 67 (range 58-78), and a median of two prior therapies (range 1-8). Four of 7 had disease progression during prior BTKi therapy (3 on covalent BTKi, 1 on pirtobrutinib), while two had completed planned BTKi-containing time-limited therapy and one had discontinued for an adverse event. Four of 7 had prior ven treatment, and three of 7 had prior PI3Ki treatment. All had unmutated IGHV. Three patients had del11q and two had del17p. Three patients had BTK mutation, two had TP53 mutation, and 1 each had NOTCH1, ATM, SF3B1 and PLCG2 mutation.
No DLTs or autoimmune PI3K-related adverse events of special interest have been observed. The most common non-hematologic toxicities include diarrhea (3 grade (gr) 1, 1 gr 3 during ven before rogi initiation), and the following events in 3 patients each: ALT increased (all gr 1); arthralgia (all gr 1); bilirubin increased (2 gr 1, 1 gr 2); creatinine increased (2 gr 1, 1 gr 2); fatigue (all gr 1); fever (all gr 1); and nausea (2 gr 1, 1 gr 2). Other gr 3 events include one each of atrial fibrillation, hypercalcemia, acute kidney injury and pneumonia, all in the first cycle during ven escalation. Neutropenia was common with 3 patients with gr 4, 1 gr 3, 2 gr 2; gr 3 thrombocytopenia occurred in 1 patient, with 5 patients with gr 1-2 thrombocytopenia. One patient developed invasive Aspergillosis during the first cycle of ven, never started rogi, and died of the infection; this patient was replaced. The remaining patients continue on therapy, with the first cohort completing 11-12 cycles, and the second cohort at 3, 6, and 9 cycles.
All six evaluable patients achieved PR at their first evaluation timepoint. Two of four patients who have reached cycle 9 have achieved uMRD in peripheral blood. The first patient to reach the final response evaluation has a MRD positive CR.
The novel conformation-selective PI3Kδ inhibitor rogi has demonstrated safety in solid tumors, and here our early data suggest that daily rogi in combination with ven R may be safe and well-tolerated in relapsed refractory CLL patients, with early efficacy observed. The recommended phase 2 dose of roginolisib with ven R is 80 mg. Updated results of this ongoing study will be presented at the meeting.
DISCLOSURES
Jennifer R. Brown, MD, PhD: iOnctura - Research Funding; BeOne (BeiGene) - Research Funding; Nagoon Therapeutics - Research Funding; Nurix Therapeutics - Research Funding; Loxo/Lilly - Research Funding; AbbVie - Consultancy (Includes expert testimony); Grifols Worldwide Operations - Consultancy (Includes expert testimony); Galapagos NV - Consultancy (Includes expert testimony); Loxo/Lilly - Consultancy (Includes expert testimony); Magnet Biomedicine - Consultancy (Includes expert testimony); Acerta/AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); InnoCare Pharma Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BeOne (BeiGene) - Consultancy (Includes expert testimony); Nurix Therapeutics - Consultancy (Includes expert testimony); iOnctura - Consultancy (Includes expert testimony)